Breast cancer care has changed faster in the last few years than most women's health clinicians can track alongside a full panel. The questions arrive anyway. The patient deciding between options who wants a second opinion in plain language. The survivor five years out asking what her surveillance should actually look like. The woman with a mother and an aunt who wants to know what her own risk means.

Matthew Kurian, MD, joins WNDG for an update built for the clinician who isn't an oncologist but is frequently the first call. He'll cover where treatment has moved and why, what ctDNA monitoring is and isn't ready to do, how clinical trial access works outside academic centers, and what women's health clinicians should be watching for in the patients who come back to them between oncology visits.

Matthew Kurian, MD, is a medical oncologist at St. Elizabeth Healthcare's Yung Family Cancer Center in Edgewood, Kentucky, and Assistant Professor of Medicine at the University of Kentucky College of Medicine. His clinical practice focuses on breast and genitourinary malignancies, and he leads the breast and GU clinical trial program at St. Elizabeth, working to bring next-generation therapies into the community setting. His research spans radioligand therapy, ctDNA-based disease monitoring, and artificial intelligence in cancer care, with multiple peer-reviewed publications across those areas. He serves as Cancer Center Physician Liaison at St. Elizabeth and on the executive committee of the Kentucky Society of Clinical Oncology, where he hosts the podcast KYSCO Oncology Voices.